Table 2

IRs (95% CI) of AEs and SAEs (all cause)

RA (N=7964)PsA (N=783)UC (N=1157)PsO (N=3663)
Total tofacitinib exposure, patient-years23‚ÄČ497203825818950
Median exposure, years2.13.01.72.4
Discontinuations due to AEs, IR (95% CI) (n)7.2 (6.9 to 7.6) (1705)3.8 (3.0 to 4.8) (80)4.1 (3.3 to 4.9) (108)5.7 (5.3 to 6.3) (530)
SAEs,* IR (95% CI) (n)9.0 (8.6 to 9.4) (1913)7.0 (5.8 to 8.2) (135)8.5 (7.4 to 9.8) (210)5.5 (5.0 to 6.0) (484)
Mortality,* IR (95% CI) (n)0.2 (0.2 to 0.3) (59)0.1 (0.0 to 0.3) (2)0.1 (0.0 to 0.3) (2)0.2 (0.1 to 0.3) (17)
  • *Within 28 days of the last dose of study drug.

  • AE, adverse event; IR, incidence rate (unique patients with events per 100 patient-years); n, unique number of patients with event; N, number of patients in the disease cohort; PsA, psoriatic arthritis; PsO, psoriasis; RA, rheumatoid arthritis; SAE, serious adverse event; UC, ulcerative colitis.